In 2018, there are many companies with high growth of API, and the export volume increased by 3.2%

[pharmaceutical Station industry trends] as of April 13, most pharmaceutical listed companies have disclosed 2018 annual reports, and 119 pharmaceutical listed companies have predicted their first quarter results From the annual report and the first quarter forecast data, there are many companies with high growth in API sector, with good sustainability For example, Haixiang pharmaceutical, whose main business is API and dye raw materials, has a good momentum in the first quarter according to the company's performance forecast According to the company, thanks to the rapid growth of sales revenue of clindamycin hydrochloride series products in the international market, the revenue of the pharmaceutical sector in the quarter of 2019 is larger than that of the same period last year It is expected that the net profit attributable to shareholders of Listed Companies in the quarter of 2019 will increase by 324.41% - 369.08% year on year, reaching between 190 million yuan and 210 million yuan The main products of sincerity pharmaceutical industry include glucosamine hydrochloride APIs and preparations, torasemide injection and capsules, gastrodin APIs, ribavirin and azathioprine APIs, etc in 2018, it achieved a net profit of 97 million yuan, an increase of 46.58% after deducting Africa The main products of Minolta include valsartan, rosuvastatin, atorvastatin, clopidogrel, perindopril, esomeprazole and other APIs and intermediates In 2018, the net profit reached 96 million yuan, an increase of 77.51% after deducting Africa It is understood that at present, the main regions of API production in the world include North America and Western Europe where the pharmaceutical industry has developed for a long time, as well as China, India and Japan in Asia Western Europe, China and India are the main export bases of API According to the statistics of medical insurance chamber of Commerce, in 2017, China's API export increased by 13.71% year-on-year to US $29.117 billion, accounting for 18.8% of the global API market share, making it a major API export country In 2018, China's API exports increased by 3.2% year-on-year to US $3048 million The export volume reached 9.2972 million tons, continuing to reach a record high, with a year-on-year increase of 3.75% According to data statistics, in 2018, there were 11406 enterprises operating API export business in China, an increase of 406 on a year-on-year basis, and the number of operating enterprises has kept increasing for five consecutive years As the main force of China's API export, private enterprises have maintained a strong export vitality In 2018, the total export volume increased by 7.26% year-on-year to US $19.345 billion However, among more than 11000 API export enterprises in China, there are many small and new enterprises, and the export concentration is still low, which brings new challenges to API export In addition, with the increasing cost of FDA regulation and declaration, as well as the improvement of environmental protection and regulatory standards in China and other regions, the barriers and comprehensive costs of API and pharmaceutical excipients industries have been raised The supply pattern of upstream raw materials and price changes caused by cost changes will also be transmitted to raw and auxiliary material enterprises It is reported that now some API enterprises begin to integrate resources and constantly improve their technological research and development capabilities For example, an enterprise said that the company adheres to the business philosophy of "quality determines survival, science and technology makes the future", adheres to the development strategy of "two wheel drive of API and preparation", integrates internal and external resources, continuously improves technology research and development ability, optimizes product layout, enriches product structure, continuously improves production process, promotes green manufacturing technology, improves product quality, and improves corporate governance Improve the management level and realize the stable, healthy and sustainable development of the company Another raw material enterprise also said that the company will gradually distribute preparations from imitation to creation, from APIs and intermediates According to the introduction, the company gradually increased the research and development of innovative drugs, and further made a strategic transformation to the business structure of "combination of imitation and innovation" At present, the company has entered the research and development pipeline with a number of first-class new drugs in anti-tumor and other fields The industry said that in the future, the industry is more concerned about how pharmaceutical companies control the quality of APIs Competition will force API enterprises to improve their quality requirements, and at the same time, it will completely break the confusion of API monopoly.